Meeting
2013 ASCO Annual Meeting
Pharmacogenetics as predictor of sunitinib and mTOR inhibitors toxicity in patients with metastatic renal cell carcinoma (mRCC).
Authors
Yuksel Urun
Dana-Farber Cancer Institute, Boston, MA
Yuksel Urun , Kathryn P. Gray , Sabina Signoretti , David F. McDermott , Michael B. Atkins , Megan E. Lampron , Matthew Freedman , Toni K. Choueiri , Mark M Pomerantz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer
Sub Track
Kidney Cancer
Citation
J Clin Oncol 31, 2013 (suppl; abstr 4570)
DOI
10.1200/jco.2013.31.15_suppl.4570
Abstract #
4570
Poster Bd #
31F
Abstract Disclosures
Similar Posters
Poster
2013 Genitourinary Cancers Symposium
Interstitial lung diseases during treatment with sunitinib or mTOR inhibitors in metastatic renal cell carcinoma.
First Author: Philipp Ivanyi
Poster
2011 ASCO Annual Meeting
Polymorphisms as markers of sunitinib efficacy and toxicity in first-line treatment of renal clear cell carcinoma: Final results of a multicentric prospective study by the Spanish Oncology Genitourinary Group.
First Author: J. Garcia-Donas
Poster
2016 Genitourinary Cancers Symposium
Risk of hepatotoxicity with concurrent statin and tyrosine kinase inhibitor (TKI) or mTOR inhibitor (mTORi) in patients with metastatic renal cell carcinoma (mRCC).
First Author: Trang H. Au
Poster
2016 Genitourinary Cancers Symposium
The impact of contrast enhancement reduction on tumor response in patients with advanced renal cell carcinoma that treated with presurgical targeting therapy.
First Author: Shingo Hatakeyama